The study's results outline the barriers that small disadvantaged businesses face in pursing success in today's environment, including the ability to build capacity and satisfy corporate demand. The goals of the research findings are to close the gap and help minority businesses achieve the size, scale and capabilities necessary for global competition.
"With greater capacity, SDBs are able to operate more successfully in the public and private sectors," said Elsie L. Scott, Ph.D., CBCF's president and chief executive officer. "Their greater success expands overall economic output and generates jobs, income and wealth in the economy and especially in underserved communities."
The results reveal the following:
-- Small disadvantaged businesses still experienced an annual disparity in
revenue of $900,000 in comparison to non-minority owned small business
concerns with similar characteristics.
-- The $750,000 personal net worth ceiling of the SDB program has not been
adjusted for inflation in nine years. Therefore, the current real value
of the ceiling is $558,070.
-- The capacity of small disadvantaged businesses and the personal net
worth of their owners are closely related.
-- A personal net worth ceiling that is set too low causes other economic
hardships.
"GlaxoSmithKline and the Congressional Black Caucus Foundation
partnered together to improve ways to help small disadvantaged businesses
succeed among the competition," said Chris Viehbacher, president of U.S.
Pharmaceuticals for GSK. "This study shows the success of tha
'/>"/>
| SOURCE GlaxoSmithKline Copyright©2007 PR Newswire. All rights reserved |